Association of MicroRNAs and YRNAs with platelet function

Circulation Research

Volumn 118, Issue 3, 2016, Pages 420-432

  Kaudewitz, Dorothee ^a   Skroblin, Philipp ^a   Bender, Lukas H ^a   Barwari, Temo ^a   Willeit, Peter ^c,d   Pechlaner, Raimund ^d   Sunderland, Nicholas P ^a   Willeit, Karin ^d   Morton, Allison C ^e   Armstrong, Paul C ^g   Chan, Melissa V ^g   Lu, Ruifang ^a   Yin, Xiaoke ^a   Gracio, Filipe ^b   Dudek, Katarzyna ^a   Langley, Sarah R ^a   Zampetaki, Anna ^a   De Rinaldis, Emanuele ^b   Ye, Shu ^h   Warner, Timothy D ^g   Saxena, Alka ^b   Kiechl, Stefan ^d   Storey, Robert F ^f   Mayr, Manuel ^a   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e Sheffield Teaching Hospitals NHS Foundation Trust   (United States)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Acute coronary syndrome; Biomarkers; Blood platelet; Micro rnas; Polymorphism; Single nucleotide

Indexed keywords

ACETYLSALICYLIC ACID; ANTAGOMIR; BASIC PROTEIN; CLOPIDOGREL; METALLOPROTEINASE; MICRORNA; MICRORNA 126; MICRORNA 223; PADGEM PROTEIN; PRASUGREL; PROTEIN ADAM9; PURINERGIC P2Y12 RECEPTOR; RNA; THROMBOCYTE FACTOR 4; TICAGRELOR; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; Y RIBONUCLEIC ACID; ANTITHROMBOCYTIC AGENT; MIRN126 MICRORNA, HUMAN; MIRN126 MICRORNA, MOUSE; OLIGONUCLEOTIDE;

ACUTE CORONARY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GENETICS; METABOLISM; PROCEDURES; THROMBOCYTE; TUMOR CELL LINE;

ACUTE CORONARY SYNDROME; ANIMALS; BLOOD PLATELETS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; OLIGONUCLEOTIDES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84958571478     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.305663     Document Type: Article

References (44)

1. Olson EN. MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease. Sci Transl Med. 2014;6:239.
2. Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res. 2012;93:555-562. doi:10.1093/cvr/cvr266.
3. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, Mayr A, Weger S, Schett G, Shah A, Boulanger CM, Willeit J, Chowienczyk PJ, Kiechl S, Mayr M. Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol. 2012;60:290-299. doi:10.1016/j.jacc.2012.03.056.
4. Willeit P, Zampetaki A, Dudek K, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res. 2013;112:595-600. doi:10.1161/CIRCRESAHA.111.300539.
5. Joshi RR, Hossain R, Morton AC, Ecob R, Judge HM, Wales C, Walker JV, Karunakaran A, Storey RF. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes. Platelets. 2014;25:416- 422. doi:10.3109/09537104.2013.836175.
6. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057. doi:10.1056/NEJMoa0904327.
7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. doi:10.1056/NEJMoa0706482.
8. Harnprasopwat R, Ha D, Toyoshima T, Lodish H, Tojo A, Kotani A. Alteration of processing induced by a single nucleotide polymorphism in pri-miR-126. Biochem Biophys Res Commun. 2010;399:117-122. doi:10.1016/j.bbrc.2010.07.009.
9. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185-192. doi:10.1056/NEJMoa012673.
10. Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest. 2004;113:441-450. doi:10.1172/JCI20267.
11. Armstrong PC, Kirkby NS, Chan MV, Finsterbusch M, Hogg N, Nourshargh S, Warner TD. Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction. Blood. 2015;126:e11-e18doi:10.1182/blood-2015-01-621656.
12. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN. The endothelial-specific microRNA miR- 126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15:261- 271. doi:10.1016/j.devcel.2008.07.002.
13. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107:677-684. doi:10.1161/CIRCRESAHA.109.215566.
14. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107:810-817doi:10.1161/CIRCRESAHA.110.226357.
15. Ferroni P, Riondino S, Vazzana N, Santoro N, Guadagni F, Davì G. Biomarkers of platelet activation in acute coronary syndromes. Thromb Haemost. 2012;108:1109-1123. doi:10.1160/TH12-08-0550.
16. Fijnheer R, Frijns CJ, Korteweg J, Rommes H, Peters JH, Sixma JJ, Nieuwenhuis HK. The origin of P-selectin as a circulating plasma protein. Thromb Haemost. 1997;77:1081-1085.
17. Ferroni P, Martini F, Riondino S, La Farina F, Magnapera A, Ciatti F, Guadagni F. Soluble P-selectin as a marker of in vivo platelet activation. Clin Chim Acta. 2009;399:88-91. doi:10.1016/j.cca.2008.09.018.
18. Flierl U, Nero TL, Lim B, et al. Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. J Exp Med. 2015;212:129-137. doi:10.1084/jem.20140391.
19. Cominetti MR, Martin AC, Ribeiro JU, Djaafri I, Fauvel-Lafève F, Crépin M, Selistre-de-Araujo HS. Inhibition of platelets and tumor cell adhesion by the disintegrin domain of human ADAM9 to collagen I under dynamic flow conditions. Biochimie. 2009;91:1045-1052. doi:10.1016/j.biochi.2009.05.012.
20. Tosar JP, Gámbaro F, Sanguinetti J, Bonilla B, Witwer KW, Cayota A. Assessment of small RNA sorting into different extracellular fractions revealed by high-throughput sequencing of breast cell lines. Nucleic Acids Res. 2015;43:5601-5616. doi:10.1093/nar/gkv432.
21. van Balkom BW, Eisele AS, Pegtel DM, Bervoets S, Verhaar MC. Quantitative and qualitative analysis of small RNAs in human endothelial cells and exosomes provides insights into localized RNA processing, degradation and sorting. J Extracell Vesicles. 2015;4:26760.
22. Dhahbi JM, Spindler SR, Atamna H, Boffelli D, Mote P, Martin DI. 5'- YRNA fragments derived by processing of transcripts from specific YRNA genes and pseudogenes are abundant in human serum and plasma. Physiol Genomics. 2013;45:990-998doi:10.1152/physiolgenomics.00129.2013.
23. Thomson DW, Pillman KA, Anderson ML, Lawrence DM, Toubia J, Goodall GJ, Bracken CP. Assessing the gene regulatory properties of Argonaute-bound small RNAs of diverse genomic origin. Nucleic Acids Res. 2015;43:470-481. doi:10.1093/nar/gku1242.
24. Nicolas FE, Hall AE, Csorba T, Turnbull C, Dalmay T. Biogenesis of Y RNA-derived small RNAs is independent of the microRNA pathway. FEBS Lett. 2012;586:1226-1230. doi:10.1016/j.febslet.2012.03.026.
25. Repetto E, Lichtenstein L, Hizir Z, et al. RNY-derived small RNAs as a signature of coronary artery disease. BMC Med. 2015;13:259. doi:10.1186/s12916-015-0489-y.
26. Ninomiya S, Kawano M, Abe T, Ishikawa T, Takahashi M, Tamura M, Takahashi Y, Nashimoto M. Potential small guide RNAs for tRNase ZL from human plasma, peripheral blood mononuclear cells, and cultured cell lines. PLoS One. 2015;10:e0118631. doi:10.1371/journal.pone.0118631.
27. Kaudewitz D, Lee R, Willeit P, McGregor R, Markus HS, Kiechl S, Zampetaki A, Storey RF, Channon KM, Mayr M. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb Haemost. 2013;110:609-615. doi:10.1160/TH13-05-0368.
28. Boeckel JN, Thomé CE, Leistner D, Zeiher AM, Fichtlscherer S, Dimmeler S. Heparin selectively affects the quantification of microRNAs in human blood samples. Clin Chem. 2013;59:1125-1127. doi:10.1373/clinchem.2012.199505.
29. Grove EL, Storey RF, Würtz M. Platelet function testing in atherothrombotic disease. Curr Pharm Des. 2012;18:5379-5391.
30. Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, Gurbel PA. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010;3:556-566. doi:10.1161/CIRCGENETICS.110.958561.
31. Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM, Taubert D. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost. 2010;8:482-488. doi:10.1111/j.1538-7836.2009.03733.x.
32. Gaglia MA Jr. Ticagrelor and the prevention of cardiovascular mortality: more than just platelet inhibition? Heart. 2014;100:1739-1740. doi:10.1136/heartjnl-2014-306285.
33. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15:272-284. doi:10.1016/j.devcel.2008.07.008.
34. McAuley AK, Dirani M, Wang JJ, Connell PP, Lamoureux EL, Hewitt AW. A genetic variant regulating miR-126 is associated with sight threatening diabetic retinopathy. Diab Vasc Dis Res. 2015;12:133-138. doi:10.1177/1479164114560160.
35. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol. 2009;16:961-966. doi:10.1038/nsmb.1651.
36. Elgheznawy A, Shi L, Hu J, Wittig I, Laban H, Pircher J, Mann A, Provost P, Randriamboavonjy V, Fleming I. Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. Circ Res. 2015;117:157-165. doi:10.1161/CIRCRESAHA.117.305784.
37. Kondkar AA, Bray MS, Leal SM, Nagalla S, Liu DJ, Jin Y, Dong JF, Ren Q, Whiteheart SW, Shaw C, Bray PF. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost. 2010;8:369-378doi:10.1111/j.1538-7836.2009.03700.x.
38. Li D, Wang Y, Zhang L, Luo X, Li J, Chen X, Niu H, Wang K, Sun Y, Wang X, Yan Y, Chai W, Gartner TK, Liu J. Roles of purinergic receptor P2Y, G protein-coupled 12 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2012;32:e81-e89. doi:10.1161/ATVBAHA.111.239095.
39. Wang L, Olivecrona G, Götberg M, Olsson ML, Winzell MS, Erlinge D. ADP acting on P2Y13 receptors is a negative feedback pathway for ATP release from human red blood cells. Circ Res. 2005;96:189-196. doi:10.1161/01.RES.0000153670.07559.E4.
40. Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost. 2011;9:552-561. doi:10.1111/j.1538-7836.2010.04160.x.
41. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410-1422. doi:10.1038/nm.2538.
42. Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res. 2012;110:508-522. doi:10.1161/CIRCRESAHA.111.247445.
43. Shi R, Ge L, Zhou X, Ji WJ, Lu RY, Zhang YY, Zeng S, Liu X, Zhao JH, Zhang WC, Jiang TM, Li YM. Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity. Thromb Res. 2013;131:508-513. doi:10.1016/j.thromres.2013.02.015.
44. Mayr M, Zampetaki A, Willeit P, Willeit J, Kiechl S. MicroRNAs within the continuum of postgenomics biomarker discovery. Arterioscler Thromb Vasc Biol. 2013;33:206-214doi:10.1161/ATVBAHA.112.300141.